Thymosin alpha 1
ApprovedSmall molecule
Thymosin alpha 1 is one of 149 small molecule programs targeting Chronic Hepatitis. It is currently in Approved.
5
Indications
11
Total Trials
1
Active Trials
148
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1053 competitors in Influenza
#DrugCompanyPhaseTrials
1Thymosin alpha 1
SSun Yat-sen University
Approved
Fluzone
SanofiPreclinical
Fluzone
GSKPreclinical
Crestor
AstraZenecaPreclinical
Trexall
Alnylam PharmaceuticalsPreclinical
Quadrivalent Influenza Vaccine
SanofiPreclinical
COMIRNATY
PfizerPreclinical
Antihistamine
Arrowhead PharmaceuticalsPreclinical
Focetria
CChiltern Pesquisa Clinica Ltda
Preclinical
Influenza A/H5N1
NNational Institute of Allergy and Infectious Diseases (NIAID)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sepsis3 trials
Influenza1 trial
Metastatic NSCLC1 trial
4 more indications
Hematological Malignancies1 trial
Small Cell Lung Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Thymosin alpha 1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- SSun Yat-sen University